Roswell Park Cancer Institute - 665 Elm St - Site 062 — Buffalo, New York

Roswell Park Cancer Institute - 665 Elm St - Site 062 is a clinical research site located in Buffalo, New York, United States 14263.

Crixeo Health Trust Score: 41/100 (POOR). This profile has not yet been claimed by the site owner.

Roswell Park Cancer Institute - 665 Elm St - Site 062 has participated in 1 clinical trials.

Therapeutic areas: Solid Tumor.

Sponsors: Kadmon, a Sanofi Company.

Sponsor Feasibility Report

Trust Score: 41/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Roswell Park Cancer Institute - 665 Elm St - Site 062?

Roswell Park Cancer Institute - 665 Elm St - Site 062 has a Crixeo Trust Score of 41/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Roswell Park Cancer Institute - 665 Elm St - Site 062 conducted?

Roswell Park Cancer Institute - 665 Elm St - Site 062 has 1 clinical trials on record. Their work covers Solid Tumor.

Is Roswell Park Cancer Institute - 665 Elm St - Site 062 accredited by Crixeo Health?

Roswell Park Cancer Institute - 665 Elm St - Site 062 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Roswell Park Cancer Institute - 665 Elm St - Site 062?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.